Pladienolide B and BAY11-7082, acting as inhibitors of the spliceosome and NF-κB pathway, demonstrated therapeutic efficacy against MES GBM in this study, as showed by both in vivo and in vitro testing. This evidence concerns the gene NFKB1 and glioblastoma.